ArticlePloS one2026
A multimodal analysis suggests partial IRF8/TLR7-associated myeloid transcriptional convergence between diabetic kidney disease and Parkinson's disease.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic kidney disease (DKD) and Parkinson's disease (PD) affect different organs but share epidemiological associations and innate immune abnormalities. The extent and cellular basis of reproducible cross-disease transcriptomic convergence remain uncertain.
methodsTwo DKD glomerular and three PD substantia nigra microarray cohorts were analyzed independently and combined using disease-specific and cross-disease meta-analysis. Independent DKD single-cell RNA-sequencing, PD single-nucleus RNA-sequencing, and spatial transcriptomic datasets were used for cell-type localization and donor- or sample-level analyses. CellChat, Monocle2, scTenifoldKnk, and previously generated UNAGI-compatible outputs were used to evaluate predicted intercellular communication, transcriptional-state continua, in-silico IRF8 perturbation, and compound prioritization. Threshold, leave-one-cohort-out, root-orientation, downsampling, and statistical-unit sensitivity analyses were performed where applicable.
resultsThe original nominal-threshold intersection of 36 genes was not retained after cohort-wise multiple-testing correction. Genome-wide overlap between DKD and PD was limited in the expanded analysis. IRF8 and TLR7 showed positive effect directions in both diseases but did not pass cross-disease false-discovery-rate correction and were therefore treated as exploratory candidates. Donor-level analyses did not detect statistically significant increases in broad myeloid-lineage proportions, although the confidence intervals did not establish equivalence. Selected DKD CCL and TNF interactions were retained in both of two targeted balanced-downsampling iterations, whereas the PD TGF-β signal was sampling-sensitive. Monocle2 identified branched and partially overlapping transcriptional-state continua. Spatial analyses provided marker-supported localization evidence without treating individual spatial observations as independent replicates. In-silico IRF8 deletion predicted regulatory-network changes but was not experimentally validated. NVP-AUY922 was the highest-ranked cross-disease computational candidate, but its association was not significant after correction across the matched compound universe.
conclusionsDKD and PD show limited genome-wide overlap but partial convergence of myeloid- and microglia-enriched inflammatory signals associated with IRF8 and TLR7. These findings provide testable hypotheses rather than evidence of a conserved causal pathway or validated cross-disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.